Search Results - drug+delivery+vehicle

75 Results Sort By:
PSMA-targeted Nanoparticles for Therapy of Prostate Cancer
PSMA-targeting nanoparticle for prostate cancer therapyJHU Ref #: C10180Value Proposition:·        Engineered nanoparticle system with potent urea-based PSMA inhibitor·        Drug loaded nanoparticle·        Specific and selective tumor cytotoxicity Unmet NeedProstate cancer affects millions of men globally and is a leading cause of cancer death in...
Published: 1/22/2026   |   Inventor(s): Martin Pomper, Ronnie Mease, Sachin Chandran, Sangeeta Ray, Samuel Denmeade
Keywords(s): Cancers, Disease Indication, Drug Delivery Vehicle, Nanoparticles, Prostate Cancer, Single, Targeted Therapy, Therapeutic Matter, Therapeutics, Therapy Type
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer
Nanoparticles for Topical Drug Delivery and Treatment of Hair Growth Conditions
Nanoparticles for Topical Drug Delivery and Treatment of Hair Growth ConditionsJHU REF: [C11686]Invention novelty: This invention is a nanoparticle for topical drug delivery targeting hair growth conditions. The particle may be an effective drug delivery tool for conditions such as hirsutism (excess hair) or alopecia (hair loss).Value PropositionThis...
Published: 1/22/2026   |   Inventor(s): Sewon Kang, Amanda Nelson, Joshua Wolfe, Jennifer Sample, Xiomara Calderon-Colon, Jason Benkoski, Mellisa Theodore, Julia Patrone, Marcia Patchan, Luis Garza
Keywords(s): Drug Delivery Vehicle, Lipid, Nanoparticles, Therapeutic Matter, Therapeutics
Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities
Polymeric particles for sustained delivery of multimodal peptide therapeutics
Value Proposition·      Stability: polymeric nanoparticle encapsulation increases and sustains peptide residence time, for increased accumulation in tissue vasculature and maximize treatment effects·      Safety: use of nanoparticles reduces toxicity by confining peptide delivery to site of administration·      Flexible formulation approaches: system's...
Published: 1/22/2026   |   Inventor(s): Jordan Green, Aleksander Popel, Joel Sunshine, Ron Shmueli, Stephany Tzeng, Kristen Kozielski
Keywords(s): Biologics, Drug Delivery Vehicle, Nucleic Acid, Peptide, Polymers, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities
Cationic Polymers with Biphasic Biodegradation
Value Proposition·        Delivery Efficacy: Demonstrates more effective gene delivery to cancer associated fibroblasts (CAFs) or human primary fibroblasts than industry gold-standards such as Lipofectamine 2000 and polyethylenimine (PEI).·        Cargo Compatibility: Enables encapsulation and delivery of a wide range of cargos including, DNA, RNA,...
Published: 1/22/2026   |   Inventor(s): Stephany Tzeng, Ron Shmueli, Nupura Bhise, Joel Sunshine, Jordan Green
Keywords(s): Drug Delivery Vehicle, Polymers, Therapeutic Matter, Therapeutics
Category(s): Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities
Extracellular Vesicle mediated nucleic acid treatment in vivo
Value Proposition·       Effective: animal studies showed increased survival and decreased tumor burden in liver cancer model.·       Fewer side effects: no immunological reactions or off-target effects·       Multiple targets: targets the cancer-stroma interactionsUnmet Need·       Many current and pipeline cancer therapeutics, including therapeutic...
Published: 1/22/2026   |   Inventor(s): Ling Li, Stephen Gould, Florin Selaru
Keywords(s): Drug Delivery Vehicle, Therapeutic Matter, Therapeutics
Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities
Biopolymer Encapsulation Increases the Bioavailability and Efficacy of D-PDMP in Interfering with Atherosclerosis and Cardiac Hypertrophy in apoE-/- Transgenic Mice
INVENTION NOVELTYA novel glycolipid inhibitor anti-atherosclerosis drug compound able to enhancegastro-intestinal absorption and residence time to reduce and ameliorateeffects of arteriosclerosis VALUE PROPOSITIONDespite great success of statins (cholesterol reducing agents), little is known aboutother molecules such as glycolipids that also rise with...
Published: 1/22/2026   |   Inventor(s): Subroto Chatterjee
Keywords(s): Antagonists/Inhibitors, Cardiovascular Diseases, Disease Indication, Drug Delivery Vehicle, Non-novel, Off-the-shelf, Polymers, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities
Hexosamine Analogs for Regenerative Medicine and Diseases Associated with the Musculoskeletal System
Unmet Need:Osteoarthritis (OA) is the most common form of arthritis, affecting an estimated 32.5 million adults in the United States, with an increasing incidence as the population ages (see CDC) . OA is associated with considerable morbidity as a consequence of joint damage, resulting in pain, loss of joint range of motion, and disability. The disease...
Published: 1/22/2026   |   Inventor(s): Kevin Yarema, Jennifer Elisseeff, Jeannine Coburn, Udayanath Aich
Keywords(s): Antagonists/Inhibitors, Arthritis, Biologics, Carbohydrates, Disease Indication, Drug Delivery Mechanism, Drug Delivery Vehicle, Joint Disorders, Novel, Osteoarthritis, Predicted Novelty, Single, Small Molecules, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type
Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Rheumatology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Rheumatology > Arthritis, Clinical and Disease Specializations > Rheumatology > Osteoarthritis
Bioreducible Poly(beta-amino ester)s for siRNA Delivery
C12218: Efficient Delivery Vehicle for Controlled Gene Knockdown Novelty: This technology comprises the use of bioreducible polymer based nanoparticle system that can release siRNA cargo to the cytoplasm of cells to knockdown target gene expression in tissues. Value Proposition: Gene therapy is a developing medical field and there is a need for...
Published: 1/22/2026   |   Inventor(s): Jordan Green, Stephany Tzeng, Kristen Kozielski
Keywords(s): Biologics, Brain Cancer, Cancers, Cell Therapy, Disease Indication, Drug Delivery Vehicle, Glioma, Nucleic Acid, Polymers, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma
Injectable Peptide Hydrogel for Local and Controlled Delivery of Immunosuppressive Drugs
Value Proposition·        Localized Drug Delivery: Enables targeted delivery of immunosuppressive drugs directly to transplant sites or affected organs, minimizing systemic exposure.·        Minimize Systemic Toxicity: Local delivery enables lower drug doses and minimizes systemic drug-associated toxicity.·        Extended Drug Release: Crystallization...
Published: 1/22/2026   |   Inventor(s): Giorgio Raimondi, Joel Schneider, Poulami Majumder
Keywords(s): Disease Indication, Drug Delivery Vehicle, Hydrogel, Inflammatory Disorders, Therapeutic Matter, Therapeutics, Tissue/organ transplant rejection
Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms
Nanoparticle Modification of Human Adipose-derived Mesenchymal Stem Cells for Brain Cancer and Other Neurological Diseases
Human Adipose-derived Mesenchymal Stem Cells can be engineered to synthesize and release anti-tumor proteins and therefore can be used as “Trojan Horses”. The inventors have created a novel technology which encompasses a solution containing biodegradable, polymeric nanoparticles that is combined with Freshly-extracted Adipose Tissue (F.A.T.) (from...
Published: 1/22/2026   |   Inventor(s): Jordan Green, Alfredo Quinones-Hinojosa
Keywords(s): Biologics, Brain Cancer, Cancers, Cell Therapy, CNS and Neurological Disorders, Disease Indication, Drug Delivery Vehicle, Glioma, Nanoparticles, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Whole cell
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma
1 2 3 4 5 6 7 8 
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum